← All trials
NCT06500026
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 7, 2024
- Primary completion
- Jul 31, 2026
- Completion date
- Jul 31, 2026
- First posted
- Jul 15, 2024
- Last posted
- Aug 22, 2024
- Enrollment
- 652
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Baili Pharmaceutical GroupLead sponsor
- Baili Pharmaceutical GroupCollaborator
- Sun Yat-Sen UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.